

Notice pursuant to ASIC Class Order [CO 09/425]

Perth, Australia, 10 July 2017: As previously announced Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) is undertaking a non-underwritten offer of fully paid ordinary shares (**New Shares**) pursuant to a share purchase plan (**Offer**) to eligible shareholders, who were registered holders of Company shares as at 5pm (WST) on 4 July 2017 and whose address as recorded in the Company's share register is in Australia or New Zealand.

This notice is being released within the 24 hour period prior to the Offer being made.

The Offer will be made in accordance with the requirements of ASIC Class Order [CO 09/425] (**Class Order**).

The Company hereby notifies ASX in accordance with the Class Order that:

1. the New Shares will be issued under the Offer without disclosure to investors in accordance with Part 6D.2 of the *Corporations Act 2001* (Cth) (**Act**);
2. this notice is being given in accordance with the Class Order;
3. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company, and section 674 of the Act; and
4. as at the date of this notice, there is no information:
 - (a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - (i) the assets and liabilities, financial position and performance, profits and losses and prospect and prospects of the Company; or
 - (ii) the rights and liabilities attaching to the New Shares.

PETER GUNZBURG
Chairman
BARD1 Life Sciences Ltd